R.N.M. declares that, as a co-inventor of anti-TNF therapy, he has received royalties from the Kennedy Trust for Rheumatology Research who owned, now expired, patents on anti-TNF therapy. M.F. declares that, as a co-inventor of anti-TNF therapy, he has received royalties in the past for patents, now expired. He is currently involved in a small biotech (Enosi Therapeutics) that is trying to develop an anti-TNFR1 therapeutic. T.T. declares that he has received grants from AbbVie, Asahikasei, AYUMI, Chugai and Mitsubishi-Tanabe, and honoraria from AbbVie, Asahikasei, Astellas, Bristol-Myers Squibb, Chugai., Daiichi Sankyo., Eisai, Janssen K.K., Mitsubishi-Tanabe and Pfizer Japan. E.R.S. declares that he has participated in advisory boards, given conferences and/or received grants from Abbvie, Amgen, Celtrion, Bristol-Myers Squibb, Genzyme, Glaxo, Janssen, Lilly, Novartis, Montpellier, Pfizer, Roche, Sandoz and UCB. V.S. declares that she has been a consultant for Abbvie, Alpine Immune Sciences, Alumis, Amgen Corporation, Aria, AstraZeneca,Atom Biosciences, Bayer, BMS, Boehringer Ingelheim, Celltrion, Ermium, Genentech/Roche, Gilead, GSK, Horizon, Inmedix, Janssen, Kiniksa, Lilly, Merck, MiMedx, Novartis, Omeros, Pfizer,R-Pharma, RAPT, Regeneron, Samsung, Sandoz, Sanofi, Scipher, Setpoint, Sorrento, Spherix and Urica.